Year: 2025
Type: article
Study design: Clinical Trial
Abstract: PURPOSE: To evaluate the efficacy of a novel recombinant human thyroid-stimulating hormone (ZGrhTSH) as an alternative to thyroid hormone withdrawal (THW) in dynamic assessment of DTC patients. METHODS: This phase 3, open-label, multicenter trial, conducted across 27 sites in China, employed a self-controlled design to enroll patients. Eligible patients had previously undergone total or near-total thyroidectomy, with or without RAI therapy. During both the ZGrhTSH-stimulated phase and the THW phase, Dx-WBS and serum Tg measurements were performed on all participants. The study focused on the concordance of Dx-WBS results, stimulated Tg levels, and their combination in patients across the two phases. Additionally, the safety and immunogenicity profiles of ZGrhTSH were assessed as well. RESULTS: In the assessment of radioiodine uptake and stimulated Tg levels, ZGrhTSH demonstrated efficacy comparable to that of THW. The concordance rate for scans between the two phases was 88.2% (95% CI: 83.7-92.7%). When setting stimulated Tg levels with a cutoff of 1 ng/mL, the concordance rate was 90.4% (95% CI: 86.1-94.6%), and the concordance of scans combined with stimulated Tg was 93.6% (95% CI: 90.1-97.1%). Adverse events associated with ZGrhTSH were reported in 22 patients (10.9%), all of which were mild and transient, graded as 1 or 2. CONCLUSION: ZGrhTSH showed non-inferior performance in detecting radioiodine uptake and serum Tg, and could be an effective and safe alternative for the dynamic evaluation of DTC patients. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04971473. Registered July 7, 2021.
Authors: YanSong Lin, Qiang Wen, Wei Fu, Hui Yang, YongJu Gao, ZhiYong Li, JinXiong Huang, ZaiRong Gao, Jing Wu, ZhongWei Lv, KeYi Lu, Yue Chen, AiMin Yang, Wei OuYang, ShuiXing Zhang, HaiZhong Zhou, ZhiYong Deng, ZhiJun Chen, Yong Ding, Chao Yuan, LinFa Li, ChengHe Lin, ShiBiao Sang, ZhiFeng Cheng, YiZhuang Cheng
Institutions: Peking Union Medical College Hospital, Jilin University, Guilin Medical University, Zhengzhou University, Henan Cancer Hospital, Henan Provincial People's Hospital, First Affiliated Hospital of Xiamen University, Wuhan Union Hospital, Huazhong University of Science and Technology, Zhengzhou Central Hospital, Shanghai Tenth People's Hospital, Shanxi Medical University, First Hospital of Shanxi Medical University, Southwest Medical University, Affiliated Hospital of Southwest Medical University, First Affiliated Hospital of Xi'an Jiaotong University, Zhujiang Hospital, Southern Medical University, First Affiliated Hospital of Jinan University, Northern Jiangsu People's Hospital, Kunming Medical University, Jiangxi Provincial Cancer Hospital, Chinese PLA General Hospital, First Affiliated Hospital of Bengbu Medical College, Zhejiang Cancer Hospital, First Hospital of Jilin University, First Affiliated Hospital of Soochow University, Fourth Affiliated Hospital of Harbin Medical University, Anhui Provincial Hospital
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,490
Funder: American Thyroid Association
OpenAlex ID: W4411132512